TP53 and cancer: Since many solid tumors significantly rely on checkpoint kinase 1 (CHEK1)-mediated cell cycle arrest, especially in the absence of the tumor protein-53 (TP53) gene [5], the CHEK1 gene can be considered as a potential target during the development of novel cancer therapies.